Inlay

T1f: #NephJC 3-Year Survival Outcomes Pts who continued metformin ≥6 months after reaching CKD stage 4 demonstrated significantly higher survival (70.3%; 95% CI, 67.9–72.8) compared to those who discontinued early (63.4%; 95% CI, 60.5–66.5) 💡6.9 percentage-point difference (95% CI, 3.2–10.6)